Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.

By M. Varela, M. Real, M. Burrel, Alejandro Forner1 , 2, M. Sala, M. Brunet, C. Ayuso, L. Castells, X. Montañá, J. Llovet and 1 more. Journal of Hepatology, 2007

944 citations recorded by the source corpus.

Subfields: Hepatology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/20675725c27f5508def9807b52f37ab8c0bd90c2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. J. Llovet
2. Jordi Bruix1 , 2
3. Riccardo Lencioni
4. V. Mazzaferro
5. Alejandro Forner1 , 2
6. Andrew X. Zhu
7. María E. Reig1 , 2
8. Peter R. Galle

In Oncology

1. Jordi Bruix1 , 2
2. V. Mazzaferro
3. J. Llovet

Citations in the corpus

• EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. (2018, positive): “TACE with drug-eluting beads (TACEDEB) using calibrated doxorubicin-carrying microspheres has shown more sustained and tumour-selective drug delivery and permanent embolisation.(520) A randomised phase II study comparing the short-term outcomes of TACE-DEB and conventional TACE indicated some advant”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “This strategy has been shown to increase the local concentration of the drug with negligible systemic toxicity [166].”
• Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (2009, background): “In two previous dose escalation studies [23, 24], DC Bead”
• Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. (2016, background): “TACE can deliver higher concentrations of drug to tumors than systemic chemotherapy, while decreasing systemic exposure [8–10].”
• EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “This strategy has been shown to increase the local concentration of the drug with negligible systemic toxicity [166].”
• Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “High concentrations of doxorubicin were administered (150 mg) with neglectable systemic toxicity, since this device allows a slow release of the drug over a 1 week period [103].”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “TACE performed with drug-eluting beads (DEB-TACE) loaded with doxorubicin has been shown to modify the pharmacokinetics of the injected chemotherapy, allowing longer intratumoral exposure and less systemic exposure of the drug, reducing toxicity [522, 523].”